Saturday 17 October 2026
Export PACB’s income statement to Excel — free account
Pacific Biosciences of California, Inc.
PACB Healthcare Medical Devices
Pacific Biosciences of California, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $160.0 million, up 3.89% from fiscal 2024. In the quarter to June 2026, revenue fell 1.91%, EPS was flat, free cash flow fell 31.0% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.73
0.23
−11.73%
Follow PACB
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | 5 | 3 | 3 |
+8 more TTM periods Free account |
| (929.31%) | (273.55%) | (213.45%) | (205.90%) | ||
| (16.66%) | (15.65%) | (53.45%) | (44.70%) | ||
ROIC |
(22.22%) | 0.00% | (93.25%) | (108.83%) | |
Return on Tangible Assets |
(44.27%) | (39.14%) | (167.41%) | (142.61%) | |
Average Days of Receivables |
71.28 | 66.94 | 80.86 | 72.29 | |
Free Cash Flow per Share |
(0.26) | (0.23) | (0.40) | (0.44) | |
Free Cash Flow |
(80.48) | (71.21) | (118.92) | (131.44) | |
Capital Expenditures |
37.57 | 40.63 | (7.71) | (8.65) | |
| Other line items | |||||
Cash ROIC |
(9.49%) | (25.58%) | (12.78%) | (13.41%) | |
Accounts Receivable Turnover |
5.03 | 5.25 | 5.08 | 5.15 | |
Accounts Payable Turnover |
5.91 | 7.24 | 6.11 | 8.11 | |
Inventory Turnover |
1.76 | 1.91 | 2.11 | 1.94 | |
Average Days of Payables |
69.25 | 49.65 | 66.37 | 51.79 | |
Days of Inventory on Hand |
220.04 | 186.16 | 157.49 | 168.25 | |
Tax Rate |
0.01 | 0.01 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
55.47% | 54.90% | 60.81% | 65.91% | |
Selling, General and Administrative Expense of Revenue |
81.43% | 82.78% | 88.43% | 96.44% | |
Share Based Compensation of Revenue |
21.53% | 23.07% | 26.04% | 31.12% | |
Interest Coverage |
(18.15) | (19.16) | (79.65) | (83.51) | |
Operating CF/Net income |
0.90 | 0.87 | 0.20 | 0.24 | |
Depreciation/Fixed assets |
0.58 | 0.61 | 16.44 | 22.27 | |
Capex/Depreciation |
2.39 | 2.76 | (0.02) | (0.02) | |
Revenue per Share |
0.51 | 0.52 | 0.53 | 0.51 | |
Operating CF per Share |
(0.38) | (0.37) | (0.37) | (0.41) | |
Capex per Share |
0.12 | 0.13 | (0.03) | (0.03) | |
Capex to Sales |
(0.24) | (0.25) | 0.05 | 0.06 |
Columns are period end dates